Cat. No.: HY-P10102

Kp7-6

2 Cited Publications

Customer Review

Based on 2 publication(s) in Google Scholar

Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8⁺Fas⁺ T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors.

For research use only. We do not sell to patients.

Purity: 99.28%
CAS No.: 629628-53-1
Formula: C₄₈H₅₆N₁₀O₁₅S₂
Molecular Weight:1077.15

Storage:

Sealed storage, away from moisture.

Powder -80°C, 2 years , -20°C, 1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Kp7-6 Chemical Structure

CAS No.: 629628-53-1

Size

Price

Stock

Quantity

Sample (0.1mg)

In-stock

(In Japan)

Apply Now

Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability Get Quote Ask For Quote & Lead Time Consult sales personnel for more information Check price and availability

Bulk Inquiry

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- In Vitro
- In Vivo
Chemical Information
Publications (2)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All NF-κB Isoforms :

All Caspase Isoforms :

All JNK Isoforms :

In Vitro

Kp7-6 (1 h, 0.1-5 mM) dose-dependently inhibits apoptosis of CM cells, RINm5F cells and isolated mouse islet β-cells induced by human islet amyloid polypeptide (hA), with stronger activity in cultured insulinoma cell lines^[1].
Kp7-6 (5 mM) inhibits the activation of hA-induced active caspase-8, phosphorylated JNK1 and active caspase-3 in isolated mouse islets when used as a pre-treatment or post-treatment^[1].
Kp7-6 (300 μM; 2 h) potently inhibits the binding of FasL to Fas receptors in solid-phase ELISA assays^[2].
Kp7-6 (12.5-100 μM; 300 s) binds specifically to FasL (K_d = 11.2 μM) and Fas (K_d = 13.2 μM) with comparable affinity^[2].
Kp7-6 (0-1000 μM; 25 h) dose-dependently protects Jurkat cells against FasL-induced cytotoxicity, with a cell survival rate of >90% at the concentration of 1000 μM, and exhibits no toxicity when applied alone to Jurkat cells^[2].
Kp7-6 (0-1000 μg/mL; 3 h) dose-dependently inhibits FasL-induced apoptosis in Jurkat cells^[2].
Kp7-6 (1 mM; 2 h) activates the NF-κB signaling pathway (via IκBα phosphorylation) in FasL-stimulated Jurkat cells, inhibits ERK1/2 phosphorylation, and does not alter the activation level of JNK^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Apoptosis Analysis^[1]

Cell Line:

CM insulinoma cells, RINm5F insulinoma cells, isolated murine islet β-cells
Concentration:

0.1 mM, 0.5 mM, 1 mM, 5 mM, 10 mM
Incubation Time:

1 h
Result:

Dose-dependently suppressed hA-evoked apoptosis.
Partially but significantly suppressed apoptosis in CM and RINm5F cells at 0.5-1 mM.
Completely suppressed apoptosis in both cell lines at 5 mM.
Exhibited more potent protective effect in cultured cell lines than in isolated islets.
Effectively inhibited apoptosis in all three β-cell systems.
Showed similar rescue effect between cultured cell lines and islet β-cells.

Cell Cytotoxicity Assay^[2]

Cell Line:

Jurkat cells
Concentration:

10, 100, 1000 μM
Incubation Time:

1 h (preincubation with FasL); 24 h (incubation with cells before [³H]thymidine pulsing)
Result:

Showed dose-dependent inhibitory activity against FasL-induced cytotoxicity.
Protected >90% of Jurkat cells from Fas-mediated cytotoxicity at the highest tested concentration.
Did not mediate cytotoxicity to Jurkat cells at the tested concentrations.

Apoptosis Analysis^[2]

Cell Line:

Jurkat cells
Concentration:

300, 1000 μg/mL
Incubation Time:

3 h
Result:

Dose-dependently reduced the percentage of annexin V-positive apoptotic Jurkat cells treated with FasL.
Reduced apoptotic cells to 31.5% at 300 μg/mL, and to 21.5% at 1000 μg/mL, compared to 49.6% apoptotic cells with FasL alone.

Western Blot Analysis^[2]

Cell Line:

Jurkat cells
Concentration:

1 mM
Incubation Time:

2 h (preincubation with cells before FasL treatment)
Result:

Enhanced phosphorylation of IκBα in the presence of FasL at 5 min.
Significantly inhibited phosphorylation of ERK1/2 at 5-30 min compared to treatment with FasL alone.
Had no effect on JNK activation.

In Vivo

Kp7-6 (3 mg per mouse; i.p.; single dose) significantly reduces Con A-induced liver injury in C57BL-6 mice, as measured by decreased serum ALT and AST activities^[2].
Kp7-6 (100 mg/kg; i.p.; daily) reduces tumor FasL levels, increases CD8⁺Fas⁺ T cell infiltration, and significantly decreases tumor weight in Rip1-Tag2 pancreatic neuroendocrine tumor mice^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

C57BL-6 (8-week-old)^[2]
Dosage:

3 mg per mouse
Administration:

i.p.; single dose
Result:

Reduced serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) activities significantly (P < 0.01 vs.
Con A-treated mice).

Animal Model:

Rip1-Tag2 (C57BL/6 background; 12 weeks old; spontaneous pancreatic neuroendocrine tumor model)^[3]
Dosage:

100 mg/kg
Administration:

i.p.; daily
Result:

Significantly reduced tumor FasL levels compared to vehicle controls.
Increased infiltration of CD8+Fas+ T cells in tumor tissues compared to vehicle controls.
Significantly decreased tumor weight compared to vehicle controls.
Left ACSS2 expression in tumor tissues unchanged compared to vehicle controls.

Chemical Information

CAS No. 629628-53-1
Appearance Solid
Molecular Weight 1077.15
Formula C₄₈H₅₆N₁₀O₁₅S₂
Color White to off-white
Sequence

Tyr-Cys-Asp-Glu-His-Phe-Cys-Tyr (Disulfide bridge:Cys2-Cys7)
Sequence Shortening

YCDEHFCY (Disulfide bridge:Cys2-Cys7)
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Sealed storage, away from moisture

Powder	-80°C	2 years
	-20°C	1 year

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Publications (2)

All

Sort by:

Journal Impact Factor

Adv Sci (Weinh)

ACSS2/AATF Drives Soluble FasL-Mediated CD8+ T Cell Apoptosis in Pancreatic Neuroendocrine Tumors. [Abstract]

2025 Aug 12:e06883. PMID: 40791180
Cell Rep Med

Tumor-infiltrated double-negative regulatory T cells predict outcome of T cell-based immunotherapy in nasopharyngeal carcinoma. [Abstract]

2025 Apr 25:102096. PMID: 40315843

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (92.84 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

0.9284 mL

4.6419 mL

9.2838 mL

5 mM

0.1857 mL

0.9284 mL

1.8568 mL

10 mM

0.0928 mL

0.4642 mL

0.9284 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline

Solubility: ≥ 2.5 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: ≥ 2.5 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil

Solubility: ≥ 2.5 mg/mL (2.32 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (293 KB)
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Portuguese - PT (252 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Zhang S, et al. Fas-associated death receptor signaling evoked by human amylin in islet beta-cells. Diabetes. 2008;57(2):348-356. [Content Brief]

[2]. Hasegawa A, et al. Fas-disabling small exocyclic peptide mimetics limit apoptosis by an unexpected mechanism. Proc Natl Acad Sci U S A. 2004;101(17):6599-6604. [Content Brief]

[3]. Dang Q, et al. ACSS2/AATF Drives Soluble FasL-Mediated CD8⁺ T Cell Apoptosis in Pancreatic Neuroendocrine Tumors. Adv Sci (Weinh). 2025;12(40):e06883. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	0.9284 mL	4.6419 mL	9.2838 mL	23.2094 mL
	5 mM	0.1857 mL	0.9284 mL	1.8568 mL	4.6419 mL
	10 mM	0.0928 mL	0.4642 mL	0.9284 mL	2.3209 mL
	15 mM	0.0619 mL	0.3095 mL	0.6189 mL	1.5473 mL
	20 mM	0.0464 mL	0.2321 mL	0.4642 mL	1.1605 mL
	25 mM	0.0371 mL	0.1857 mL	0.3714 mL	0.9284 mL
	30 mM	0.0309 mL	0.1547 mL	0.3095 mL	0.7736 mL
	40 mM	0.0232 mL	0.1160 mL	0.2321 mL	0.5802 mL
	50 mM	0.0186 mL	0.0928 mL	0.1857 mL	0.4642 mL
	60 mM	0.0155 mL	0.0774 mL	0.1547 mL	0.3868 mL
	80 mM	0.0116 mL	0.0580 mL	0.1160 mL	0.2901 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Kp7-6

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

MAPK Compound Library

NF-κB Signaling Compound Library

Stem Cell Signaling Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Antioxidant Compound Library

Reprogramming Compound Library

Anti-diabetic Compound Library

Oxygen Sensing Compound Library

Endoplasmic Reticulum Stress Compound Library

Pyroptosis Compound Library

Anti-Breast Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Anti-Obesity Compound Library

Transcription Factor-Targeted Library

Peptide Library

Antidepressant Compound Library

Anti-Pulmonary Fibrosis Compound Library

Pain-Related Compound Library

Protease Inhibitor Library

Highly Selective Inhibitors Library

Highly Selective Activators Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Multi-Target Compound Library

Radioprotector Library

Bioactive Compound Library Max

Peptide Compound Library

Bioactive Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

Lactylation Compound Library

Publications Citing Use of MedChemExpress (MCE) Kp7-6

All NF-κB Isoforms

All Caspase Isoforms

All JNK Isoforms

Biological Activity

Chemical Information

Publications (2)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Kp7-6 Related Classifications

Cat. No.: HY-P10102